O	0	1	A
O	2	12	randomized
O	13	18	trial
O	19	28	comparing
B-intervention	29	33	live
I-intervention	34	37	and
I-intervention	38	50	telemedicine
I-intervention	51	61	deliveries
I-intervention	62	64	of
I-intervention	65	67	an
I-intervention	68	75	imagery
I-intervention	75	76	-
I-intervention	76	81	based
I-intervention	82	92	behavioral
O	93	105	intervention
O	106	109	for
O	110	116	breast
O	117	123	cancer
O	124	133	survivors
O	133	134	:
O	135	143	reducing
O	144	152	symptoms
O	153	156	and
O	157	165	barriers
O	166	168	to
O	169	173	care
O	173	174	.

O	175	179	This
O	180	185	multi
O	185	186	-
O	186	190	site
O	191	201	randomized
O	202	207	trial
O	208	217	evaluates
O	218	221	the
O	222	229	quality
O	230	232	of
O	233	237	life
O	238	239	(
O	239	242	QOL
O	242	243	)
O	244	252	benefits
O	253	255	of
O	256	258	an
O	259	266	imagery
O	266	267	-
O	267	272	based
O	273	278	group
O	279	291	intervention
O	292	298	titled
O	299	300	'
O	300	308	Envision
O	309	312	the
O	313	320	Rhythms
O	321	323	of
O	324	328	Life
O	328	329	'
O	329	330	(
O	330	333	ERL
O	333	334	)
O	334	335	.

B-eligibility	336	342	Breast
I-eligibility	343	349	cancer
I-eligibility	350	359	survivors
I-eligibility	360	361	>
I-eligibility	361	362	6
I-eligibility	363	368	weeks
I-eligibility	369	373	post
I-eligibility	373	374	-
I-eligibility	374	383	treatment
O	384	388	were
O	389	399	randomized
O	400	402	to
O	403	409	attend
O	410	414	five
O	415	421	weekly
O	422	423	4
O	423	424	-
O	424	425	h
O	426	431	group
O	432	440	sessions
O	441	443	at
O	444	445	a
O	446	455	community
O	456	462	center
O	463	467	with
O	468	477	therapist
O	478	485	present
O	486	487	(
O	487	491	live
O	492	500	delivery
O	501	502	(
O	502	504	LD
O	504	505	)
O	505	506	,
O	507	508	n
O	509	510	=
B-intervention-participants	511	513	48
O	513	514	)
O	514	515	,
O	516	525	therapist
O	526	534	streamed
O	535	538	via
O	539	551	telemedicine
O	552	553	(
O	553	565	telemedicine
O	566	574	delivery
O	575	576	(
O	576	578	TD
O	578	579	)
O	579	580	,
O	581	582	n
O	583	584	=
B-intervention-participants	585	587	23
O	587	588	)
O	588	589	,
O	590	592	or
O	593	595	to
O	596	597	a
B-control	598	606	waitlist
I-control	607	614	control
I-control	615	616	(
I-control	616	618	WL
I-control	618	619	)
O	620	625	group
O	626	627	(
O	627	628	n
O	629	630	=
B-control-participants	631	633	47
O	633	634	)
O	634	635	.

O	636	642	Weekly
O	643	653	individual
O	654	659	phone
O	660	665	calls
O	666	668	to
O	669	678	encourage
O	679	681	at
O	681	682	-
O	682	686	home
O	687	695	practice
O	696	701	began
O	702	704	at
O	705	712	session
O	713	716	one
O	717	720	and
O	721	730	continued
O	731	736	until
O	737	740	the
O	741	742	3
O	742	743	-
O	743	748	month
O	749	755	follow
O	755	756	-
O	756	758	up
O	758	759	.

O	760	765	Seven
O	766	770	self
O	770	771	-
O	771	777	report
O	778	786	measures
O	787	789	of
O	790	793	QOL
O	794	798	were
O	799	807	examined
O	808	810	at
O	811	819	baseline
O	819	820	,
O	821	822	1
O	822	823	-
O	823	828	month
O	829	832	and
O	833	834	3
O	834	835	-
O	835	840	month
O	841	845	post
O	845	846	-
O	846	856	treatments
O	857	866	including
O	867	873	health
O	873	874	-
O	874	881	related
O	882	885	and
O	886	892	breast
O	893	899	cancer
O	899	900	-
O	900	908	specific
O	909	912	QOL
O	912	913	,
O	914	921	fatigue
O	921	922	,
O	923	932	cognitive
O	933	941	function
O	941	942	,
O	943	955	spirituality
O	955	956	,
O	957	965	distress
O	965	966	,
O	967	970	and
O	971	976	sleep
O	976	977	.

O	978	981	The
O	982	992	Bonferroni
O	993	999	method
O	1000	1003	was
O	1004	1008	used
O	1009	1011	to
O	1012	1019	correct
O	1020	1023	for
O	1024	1032	multiple
O	1033	1044	comparisons
O	1044	1045	,
O	1046	1049	and
O	1050	1055	alpha
O	1056	1059	was
O	1060	1068	adjusted
O	1069	1071	to
O	1072	1073	0
O	1073	1074	.
O	1074	1076	01
O	1076	1077	.

O	1078	1084	Linear
O	1085	1095	multilevel
O	1096	1104	modeling
O	1105	1113	analyses
O	1114	1122	revealed
O	1123	1127	less
B-outcome	1128	1135	fatigue
O	1135	1136	,
B-outcome	1137	1146	cognitive
I-outcome	1147	1158	dysfunction
O	1158	1159	,
O	1160	1163	and
B-outcome	1164	1169	sleep
I-outcome	1170	1181	disturbance
O	1182	1185	for
O	1186	1188	LD
O	1189	1192	and
O	1193	1195	TD
O	1196	1204	compared
O	1205	1209	with
O	1210	1212	WL
O	1213	1219	across
O	1220	1223	the
O	1224	1230	follow
O	1230	1231	-
O	1231	1233	up
O	1234	1235	(
O	1235	1236	p
O	1236	1237	'
O	1237	1238	s
O	1239	1240	<
O	1241	1242	0
O	1242	1243	.
O	1243	1245	01
O	1245	1246	)
O	1246	1247	.

O	1248	1255	Changes
O	1256	1258	in
B-outcome	1259	1266	fatigue
O	1266	1267	,
B-outcome	1268	1277	cognitive
I-outcome	1278	1289	dysfunction
O	1289	1290	,
B-outcome	1291	1296	sleep
I-outcome	1297	1308	disturbance
O	1308	1309	,
O	1310	1313	and
B-outcome	1314	1320	health
I-outcome	1320	1321	-
I-outcome	1321	1328	related
I-outcome	1329	1332	and
I-outcome	1333	1339	breast
I-outcome	1340	1346	cancer
I-outcome	1346	1347	-
I-outcome	1347	1354	related
I-outcome	1355	1358	QOL
O	1359	1363	were
O	1364	1374	clinically
O	1375	1386	significant
O	1386	1387	.

O	1388	1393	There
O	1394	1398	were
O	1399	1401	no
O	1402	1413	differences
O	1414	1421	between
B-outcome	1422	1424	LD
O	1425	1428	and
B-outcome	1429	1431	TD
O	1431	1432	.

O	1433	1437	Both
O	1438	1441	the
O	1442	1446	live
O	1447	1450	and
O	1451	1463	telemedicine
O	1464	1473	delivered
O	1474	1477	ERL
O	1478	1490	intervention
O	1491	1499	resulted
O	1500	1502	in
O	1503	1515	improvements
O	1516	1518	in
O	1519	1527	multiple
B-outcome	1528	1531	QOL
O	1532	1539	domains
O	1540	1543	for
O	1544	1550	breast
O	1551	1557	cancer
O	1558	1567	survivors
O	1568	1576	compared
O	1577	1581	with
O	1582	1584	WL
O	1584	1585	.

O	1586	1593	Further
O	1593	1594	,
O	1595	1600	there
O	1601	1605	were
O	1606	1608	no
O	1609	1620	significant
O	1621	1632	differences
O	1633	1640	between
O	1641	1643	LD
O	1644	1647	and
O	1648	1650	TD
O	1650	1651	,
O	1652	1662	suggesting
O	1663	1675	telemedicine
O	1676	1685	delivered
O	1686	1689	ERL
O	1690	1702	intervention
O	1703	1706	may
O	1707	1716	represent
O	1717	1719	an
O	1720	1729	effective
O	1730	1733	and
O	1734	1740	viable
O	1741	1747	option
O	1748	1751	for
O	1752	1758	cancer
O	1759	1768	survivors
O	1769	1771	in
O	1772	1778	remote
O	1779	1784	areas
O	1784	1785	.
